Chardan Capital Weighs in on uniQure FY2025 Earnings

uniQure (NASDAQ:QURE - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for uniQure in a report released on Tuesday, April 1st. Chardan Capital analyst Y. Livshits expects that the biotechnology company will earn ($3.90) per share for the year. Chardan Capital has a "Buy" rating and a $38.00 price objective on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share. Chardan Capital also issued estimates for uniQure's FY2026 earnings at ($3.23) EPS.

Several other equities research analysts also recently commented on the stock. Leerink Partners upped their target price on shares of uniQure from $26.00 to $44.00 and gave the company an "outperform" rating in a research note on Wednesday, December 11th. StockNews.com upgraded shares of uniQure to a "sell" rating in a research report on Tuesday, March 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Stifel Nicolaus increased their price target on uniQure from $12.00 to $32.00 and gave the stock a "buy" rating in a report on Monday, December 16th. Finally, Guggenheim reaffirmed a "buy" rating on shares of uniQure in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, uniQure currently has an average rating of "Moderate Buy" and a consensus price target of $38.80.

uniQure Trading Down 1.5 %

Shares of NASDAQ:QURE traded down $0.13 during mid-day trading on Thursday, reaching $8.63. The stock had a trading volume of 395,708 shares, compared to its average volume of 1,671,390. The firm has a 50 day simple moving average of $13.11 and a two-hundred day simple moving average of $11.00. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The firm has a market cap of $466.68 million, a PE ratio of -1.74 and a beta of 0.42. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Twin Tree Management LP acquired a new position in uniQure during the fourth quarter worth $77,000. FNY Investment Advisers LLC acquired a new position in shares of uniQure during the 4th quarter worth about $88,000. RTW Investments LP bought a new stake in shares of uniQure in the 3rd quarter valued at about $49,000. ADAR1 Capital Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at about $177,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares during the period. Institutional investors own 78.83% of the company's stock.

Insiders Place Their Bets

In related news, CFO Christian Klemt sold 2,916 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares in the company, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last quarter. 4.74% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.